BACKGROUND: @entity7154 is a non-steroidal anti-inflammatory drug (NSAID). It is most often used for treating @entity158 of dysmenorrhoea in the short term (seven days or less), as well as mild to moderate @entity158 including @entity10 , @entity158 . It is widely available in many countries worldwide. OBJECTIVES: To assess the efficacy of single dose oral @entity7154 in @entity282 , and any associated adverse events. SEARCH STRATEGY: We searched Cochrane CENTRAL, MEDLINE, EMBASE and the Oxford @entity158 Relief Database for studies to December 2010. SELECTION CRITERIA: Single oral dose, randomised, double-blind, placebo-controlled trials of @entity7154 for relief of established moderate to severe @entity282 in adults. DATA COLLECTION AND ANALYSIS: Studies were assessed for methodological quality and the data extracted by two review authors independently. Summed total @entity158 relief (TOTPAR) or @entity158 intensity difference (SPID) over 4 to 6 hours was used to calculate the number of @entity1 achieving at least 50% @entity158 relief. These derived results were used to calculate, with 95% confidence intervals, the relative benefit compared to placebo, and the number needed to treat (NNT) for one @entity1 to experience at least 50% @entity158 relief over 4 to 6 hours. Numbers of @entity1 using rescue medication over specified time periods, and time to use of rescue medication, were sought as additional measures of efficacy. Information on adverse events and withdrawals was collected. MAIN RESULTS: Four studies with 842 @entity1 met the inclusion criteria; 126 @entity1 were treated with @entity7154 500 mg, 67 with @entity7154 250 mg, 197 with placebo, and 452 with @entity3303 , @entity117 , @entity70195 or @entity9695 . @entity1 had @entity158 following third molar extraction, episiotomy and orthopaedic surgery. The NNT for at least 50% @entity158 relief over 6 hours with a single dose of @entity7154 500 mg compared to placebo was 4.0 (2.7 to 7.1), and the NNT to prevent use of rescue medication over 6 hours was 6.5 (3.6 to 29). There were insufficient data to analyse other doses or active comparators, or numbers of @entity1 experiencing any adverse events. No serious adverse events or adverse event withdrawals were reported in these studies. AUTHORS' CONCLUSIONS: Oral @entity7154 500 mg was effective at treating moderate to severe @entity282 , based on limited data. Efficacy of other doses, and safety and tolerability could not be assessed.

Single dose oral @entity7154 for XXXX in adults.

@entity1 :: ('9606', 'Species') :: ['participants', 'participant', 'Participants'] @entity70195 :: ('MESH:C020549', 'Chemical') :: ['zomepirac'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lignocaine'] @entity7154 :: ('MESH:D008528', 'Chemical') :: ['Mefenamic acid', 'mefenamic acid'] @entity158 :: ('MESH:D010146', 'Disease') :: ['dental pain, postoperative and postpartum pain', 'Pain', 'pain'] @entity9695 :: ('MESH:C012655', 'Chemical') :: ['nimesulide'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headache'] @entity282 :: ('MESH:D010149', 'Disease') :: ['acute postoperative pain', 'postoperative pain']
@entity282 :: (MESH:D010149,Disease) :: ['acute postoperative pain']
